Why Do Regulations E...
2018 A Year of Micro...
3rd April 2019 Content supplied by: Mast Group Ltd
NEW MAST® CARBA PAcE Rapid, Simple and Cost Effective Carbapenemase Detection
Mast Group Ltd have announced the launch of the NEW MAST® CARBA PAcE for rapid carbapenemase detection in Pseudomonas, Acinetobacter and Enterobacterales.
Increasing antimicrobial resistance is one of the most urgent global challenges facing the field of healthcare. Carbapenem resistant bacteria are an emerging cause of healthcare associated infection and are particularly concerning due to the high level of antimicrobial resistance coupled with the ability for widespread transmission. It is important to detect carriers quickly to prevent and control spread and so aid antimicrobial stewardship.
Mast Group Ltd. has developed a colorimetric test which rapidly detects carbapenemase producing Pseudomonas spp., Acinetobacter spp. and Enterobacterales using a novel chromogenic cephalosporin analogue.
- Rapid results in less than 10 minutes
- Simple test process in 5 easy steps
- Cost effective screening solution
- High sensitivity and specificity
MAST® CARBA PAcE – rapid, simple, cost effective – visit Mast Group Ltd. at ECCMID on stand 1.7a for more information on how to simplify your carbapenemase detection.
Date Published: 3rd April 2019
Source article link: View
Why Do Regulations Expect a
2018 A Year of Microbiome Investments